Xiaoqun Zhang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Xiaoqun Zhang has a total of 79 co-authors. Here are the top co-authors by number of shared publications:
- Per Svenningsson
Department of Basal and Clinical Neuroscience, King’s College London, London, UK
10 shared publications - Daniel Dautan
Department of Clinical Neuroscience, Karolinska Institute, Stockholm, Sweden
3 shared publications - Roberta Marongiu
Department of Neurological Surgery, Weill Cornell Medicine, New York, NY, United States
3 shared publications - Daniel C. Doyon
Department of Clinical Neuroscience, Karolinska Institute, Stockholm, Sweden
2 shared publications Daniel Doyon
Department of Clinical Neuroscience, Karolinska Institute, Stockholm, Sweden
2 shared publications- Dennis J. Selkoe
Ann Romney Center for Neurologic Diseases, Department of Neurology, Brigham and Women’s Hospital and Harvard Medical School, Boston, USA
2 shared publications
Latest Publications
- Open Access
- 10 March 2026
- Published by Springer Nature in Translational Neurodegeneration
- Vol. 15 (1) , 10
Gut-initiated alpha synuclein fibrils drive parkinsonism phenotypes: temporal mapping of REM sleep behavior disorder-like and other non-motor symptoms
Background: Parkinson’s disease (PD) is a progressive neurodegenerative disorder marked by both motor and non-motor symptoms. Although non-motor features such as gastrointestinal and sleep disturbances often precede motor impairments and are critical to PD pathogenesis, the mechanisms underlying their onset and progression remain insufficiently characterized. Methods: To investigate the sequential development of motor and non-motor symptoms in a model of experimental parkinsonism, we injected alpha-synuclein (αSyn) preformed fibrils (PFFs) into the duodenum and antrum of wild-type mice, establishing a gut-brain axis model of PD. We performed whole-brain anatomical mapping of αSyn-PFF propagation and assessed behavioral alterations at multiple time points post-injection. Correlations between anatomical spread and behavioral changes, particularly sleep, were further validated through SNCA overexpression or local αSyn-PFF injections in the substantia nigra, combined with dual-wavelength fiber photometry, behavioral assays, and histological analyses. Results: Injection of αSyn-PFFs into the gastrointestinal tract of wild-type mice led to a progressive spread of pathological αSyn throughout the central nervous system, in temporal association with distinct motor and non-motor phenotypes. These findings provide translational validity of the gut-brain model, mirroring the clinical progression seen in many PD patients. In two established αSyn-based PD models, dual-wavelength fiber photometry that monitors dopamine and acetylcholine release in the striatum, demonstrated a central role for dopamine dysfunction in modulating sleep architecture, particularly in relation to REM sleep without atonia, consistent with REM sleep behavior disorder (RBD)-like manifestations in PD. Conclusion: This work provides a detailed characterization of the progressive and multisystem nature of experimental parkinsonism, highlighting the interplay between αSyn pathology, gut-brain signaling, and the onset of non-motor disturbances, with a particular focus on RBD-like alterations in sleep.
- 10 March 2026
- Published by Springer Nature in Translational Neurodegeneration
- Vol. 15 (1) , 10
Open AccessGut-initiated alpha synuclein fibrils drive parkinsonism phenotypes: temporal mapping of REM sleep behavior disorder-like and other non-motor symptoms
Background: Parkinson’s disease (PD) is a progressive neurodegenerative disorder marked by both motor and non-motor symptoms. Although non-motor features such as gastrointestinal and sleep disturbances often precede motor impairments and are critical to PD pathogenesis, the mechanisms underlying their onset and progression remain insufficiently characterized. Methods: To investigate the sequential development of motor and non-motor symptoms in a model of experimental parkinsonism, we injected alpha-synuclein (αSyn) preformed fibrils (PFFs) into the duodenum and antrum of wild-type mice, establishing a gut-brain axis model of PD. We performed whole-brain anatomical mapping of αSyn-PFF propagation and assessed behavioral alterations at multiple time points post-injection. Correlations between anatomical spread and behavioral changes, particularly sleep, were further validated through SNCA overexpression or local αSyn-PFF injections in the substantia nigra, combined with dual-wavelength fiber photometry, behavioral assays, and histological analyses. Results: Injection of αSyn-PFFs into the gastrointestinal tract of wild-type mice led to a progressive spread of pathological αSyn throughout the central nervous system, in temporal association with distinct motor and non-motor phenotypes. These findings provide translational validity of the gut-brain model, mirroring the clinical progression seen in many PD patients. In two established αSyn-based PD models, dual-wavelength fiber photometry that monitors dopamine and acetylcholine release in the striatum, demonstrated a central role for dopamine dysfunction in modulating sleep architecture, particularly in relation to REM sleep without atonia, consistent with REM sleep behavior disorder (RBD)-like manifestations in PD. Conclusion: This work provides a detailed characterization of the progressive and multisystem nature of experimental parkinsonism, highlighting the interplay between αSyn pathology, gut-brain signaling, and the onset of non-motor disturbances, with a particular focus on RBD-like alterations in sleep.
- Open Access
- 9 December 2025
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Ultra-large virtual screening unveils potent agonists of the neuromodulatory orphan receptor GPR139
The orphan G protein-coupled receptor (GPCR) GPR139 attracts interest as a target for neuropsychiatric disorders. Whereas the physiological functions of GPR139 remain elusive, a high-resolution receptor structure is now available. To assess whether structural information enables ligand discovery, we computationally dock 235 million compounds to the GPR139 binding site. Of 68 top-ranked compounds evaluated experimentally, five are full agonists with potencies ranging from 160 nM to 3.6 µM. Structure-guided optimization identifies one of the most potent GPR139 agonists, and a cryo-EM structure of the receptor-ligand complex confirms the predicted binding mode. Functional characterization provides insights into GPR139 signalling, and one agonist elicits behavioural effects in mice. We also explore the potential to replace experimental structure determination with the deep-learning method AlphaFold3, revealing a limited capability of artificial intelligence to model receptor-ligand interactions for understudied GPCRs. The results demonstrate how high-resolution GPCR structures combined with large-library docking can accelerate drug discovery.
- 9 December 2025
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Open AccessUltra-large virtual screening unveils potent agonists of the neuromodulatory orphan receptor GPR139
The orphan G protein-coupled receptor (GPCR) GPR139 attracts interest as a target for neuropsychiatric disorders. Whereas the physiological functions of GPR139 remain elusive, a high-resolution receptor structure is now available. To assess whether structural information enables ligand discovery, we computationally dock 235 million compounds to the GPR139 binding site. Of 68 top-ranked compounds evaluated experimentally, five are full agonists with potencies ranging from 160 nM to 3.6 µM. Structure-guided optimization identifies one of the most potent GPR139 agonists, and a cryo-EM structure of the receptor-ligand complex confirms the predicted binding mode. Functional characterization provides insights into GPR139 signalling, and one agonist elicits behavioural effects in mice. We also explore the potential to replace experimental structure determination with the deep-learning method AlphaFold3, revealing a limited capability of artificial intelligence to model receptor-ligand interactions for understudied GPCRs. The results demonstrate how high-resolution GPCR structures combined with large-library docking can accelerate drug discovery.
- Open Access
- 3 November 2025
- Published by Springer Nature in Molecular Psychiatry
- Vol. 31 (3) , 1785-1798
Altered acetylcholine modulations and corticoaccumbal pathway in P11-linked social dysfunction
Social relationships rely on the willingness to interact with others and the ability to interpret their emotional cues. Major depressive disorder (MDD) often leads to dysfunctional social interactions, marked by reduced social motivation and difficulties in recognizing emotions, yet these issues remain inadequately explored despite their significant impact on quality of life. These social behaviors, interconnected through the corticoaccumbal pathway, balance anxiety and social interaction, but the underlying mechanisms remain poorly understood. Notably, the calcium-binding protein S100A10 (also known as P11), which is dysregulated in MDD patients and influences the response to antidepressants, is prominently expressed in brain structures involved in social and emotional processing. Here, we demonstrate that chronic restraint stress alters P11 expression along the corticoaccumbal circuit. Additionally, our genetic model, P11-knockout mice, exhibit depression-like behavior, including a reduction of social motivation and impaired recognition of conspecific emotions. Using in vivo and ex vivo electrophysiology, we reveal that P11 expression modulates the response of the corticoaccumbal pathway, influencing the balance between anxiety and social interaction, as well as emotion recognition by regulating dopamine and acetylcholine release in the accumbens. Interestingly, we pinpoint the role of different cholinergic structures in anxiety, social motivation, and emotion recognition. Finally, we show that the prosocial compound oxytocin and social buffering therapy were able to rescue the socially impaired behaviors following chronic stress or P11 ablation, opening new avenues for potential treatments.
- 3 November 2025
- Published by Springer Nature in Molecular Psychiatry
- Vol. 31 (3) , 1785-1798
Open AccessAltered acetylcholine modulations and corticoaccumbal pathway in P11-linked social dysfunction
Social relationships rely on the willingness to interact with others and the ability to interpret their emotional cues. Major depressive disorder (MDD) often leads to dysfunctional social interactions, marked by reduced social motivation and difficulties in recognizing emotions, yet these issues remain inadequately explored despite their significant impact on quality of life. These social behaviors, interconnected through the corticoaccumbal pathway, balance anxiety and social interaction, but the underlying mechanisms remain poorly understood. Notably, the calcium-binding protein S100A10 (also known as P11), which is dysregulated in MDD patients and influences the response to antidepressants, is prominently expressed in brain structures involved in social and emotional processing. Here, we demonstrate that chronic restraint stress alters P11 expression along the corticoaccumbal circuit. Additionally, our genetic model, P11-knockout mice, exhibit depression-like behavior, including a reduction of social motivation and impaired recognition of conspecific emotions. Using in vivo and ex vivo electrophysiology, we reveal that P11 expression modulates the response of the corticoaccumbal pathway, influencing the balance between anxiety and social interaction, as well as emotion recognition by regulating dopamine and acetylcholine release in the accumbens. Interestingly, we pinpoint the role of different cholinergic structures in anxiety, social motivation, and emotion recognition. Finally, we show that the prosocial compound oxytocin and social buffering therapy were able to rescue the socially impaired behaviors following chronic stress or P11 ablation, opening new avenues for potential treatments.
- Open Access
- 12 September 2025
- Published by Wiley in Chemistry–Methods
- Vol. 5 (12)
Derivatization of Small Molecules using Deuterated Analog of Reactive Matrix to Facilitate Identification in Mass Spectrometry Imaging
Mass spectrometry imaging (MSI) is a powerful tool for spatial metabolomics and biomarker discovery, but molecular identification remains challenging, particularly for low‐abundance analytes with poor signal‐to‐noise ratios. Herein, a novel approach that utilizes a deuterated analog of the reactive matrix FMP‐10 to enhance molecular identification is introduced. This isotopically labeled matrix enables precise determination of derivatization patterns, allowing the number and sequence of reactive functional groups in small molecules to be deduced. By observing specific mass shifts, the method provides additional structural information beyond high‐resolution MS and MS/MS, addressing key limitations in MSI‐based biomarker discovery. This innovative labeling strategy improves identification confidence for neurotransmitters and metabolites, making it a powerful addition to the MSI toolbox for complex tissue analysis. The findings represent a significant advance for spatial metabolomics, with particular advantages for neurochemical mapping in the study of neurodegenerative diseases.
- 12 September 2025
- Published by Wiley in Chemistry–Methods
- Vol. 5 (12)
Open AccessDerivatization of Small Molecules using Deuterated Analog of Reactive Matrix to Facilitate Identification in Mass Spectrometry Imaging
Mass spectrometry imaging (MSI) is a powerful tool for spatial metabolomics and biomarker discovery, but molecular identification remains challenging, particularly for low‐abundance analytes with poor signal‐to‐noise ratios. Herein, a novel approach that utilizes a deuterated analog of the reactive matrix FMP‐10 to enhance molecular identification is introduced. This isotopically labeled matrix enables precise determination of derivatization patterns, allowing the number and sequence of reactive functional groups in small molecules to be deduced. By observing specific mass shifts, the method provides additional structural information beyond high‐resolution MS and MS/MS, addressing key limitations in MSI‐based biomarker discovery. This innovative labeling strategy improves identification confidence for neurotransmitters and metabolites, making it a powerful addition to the MSI toolbox for complex tissue analysis. The findings represent a significant advance for spatial metabolomics, with particular advantages for neurochemical mapping in the study of neurodegenerative diseases.
- Open Access
- 11 February 2025
- Published by Springer Nature in Neuropsychopharmacology
- Vol. 50 (5) , 721-730
A molecular mechanism mediating clozapine-enhanced sensorimotor gating
The atypical antipsychotic clozapine targets multiple receptor systems beyond the dopaminergic pathway and influences prepulse inhibition (PPI), a critical translational measure of sensorimotor gating. Since PPI is modulated by atypical antipsychotics such as risperidone and clozapine, we hypothesized that p11—an adaptor protein associated with anxiety- and depressive-like behaviors and G-protein-coupled receptor function—might modulate these effects. In this study, we assessed the role of p11 in clozapine’s PPI-enhancing effect by testing wild-type and global p11 knockout (KO) mice in response to haloperidol, risperidone, and clozapine. We also performed structural and functional brain imaging. Contrary to our expectation that anxiety-like p11-KO mice would exhibit an augmented startle response and heightened sensitivity to clozapine, PPI tests showed that p11-KO mice were unresponsive to the PPI-enhancing effects of risperidone and clozapine. Imaging revealed distinct regional brain volume differences and reduced hippocampal connectivity in p11-KO mice, with significantly blunted clozapine-induced connectivity changes in the CA1 region. Our findings highlight a novel role for p11 in modulating clozapine’s effects on sensorimotor gating and hippocampal connectivity, offering new insight into its functional pathways.
- 11 February 2025
- Published by Springer Nature in Neuropsychopharmacology
- Vol. 50 (5) , 721-730
Open AccessA molecular mechanism mediating clozapine-enhanced sensorimotor gating
The atypical antipsychotic clozapine targets multiple receptor systems beyond the dopaminergic pathway and influences prepulse inhibition (PPI), a critical translational measure of sensorimotor gating. Since PPI is modulated by atypical antipsychotics such as risperidone and clozapine, we hypothesized that p11—an adaptor protein associated with anxiety- and depressive-like behaviors and G-protein-coupled receptor function—might modulate these effects. In this study, we assessed the role of p11 in clozapine’s PPI-enhancing effect by testing wild-type and global p11 knockout (KO) mice in response to haloperidol, risperidone, and clozapine. We also performed structural and functional brain imaging. Contrary to our expectation that anxiety-like p11-KO mice would exhibit an augmented startle response and heightened sensitivity to clozapine, PPI tests showed that p11-KO mice were unresponsive to the PPI-enhancing effects of risperidone and clozapine. Imaging revealed distinct regional brain volume differences and reduced hippocampal connectivity in p11-KO mice, with significantly blunted clozapine-induced connectivity changes in the CA1 region. Our findings highlight a novel role for p11 in modulating clozapine’s effects on sensorimotor gating and hippocampal connectivity, offering new insight into its functional pathways.
- Open Access
- 26 November 2024
- Published by Springer Nature in Molecular Psychiatry
- Vol. 30 (6) , 2504-2516
Enduring modulation of dorsal raphe nuclei regulates (R,S)-ketamine-mediated resilient stress-coping behavior
Ketamine may be a novel pharmacologic approach to enhance resilience and protect against stress-related disorders, but the molecular targets underlying this response remain to be fully characterized. The multifunctional protein p11 is crucial in the pathophysiology of depression and antidepressant responses. However, it is still unclear whether p11 plays a role in the pro-resilience effects induced by ketamine. Here, we demonstrated that prophylactic administration of ketamine buffers passive stress-induced maladaptive phenotypes induced by chronic stress exposure. Spatial neurotransmitter and metabolite analysis revealed that prophylactic ketamine was also effective in blunting stress-induced disturbances of tryptophan metabolism in dorsal raphe nuclei (DRN). Additionally, we demonstrated that ketamine prevented chronic restraint stress-induced p11 reduction in DRN, a highly p11-enriched region. Furthermore, we provide novel evidence indicating that p11 deficiency regulates susceptibility to stress-induced depression-related phenotypes, and these behavioral maladaptations are dependent, at least in part, on p11 function in serotonergic neurons. Spatial neurotransmitter and metabolite analysis also showed a reduction of tryptophan and dopamine metabolism in DRN of serotonergic p11-deficient mice. Viral-mediated downregulation of p11 within DRN induced a stress-susceptible phenotype. Finally, our results also unveiled that the ability of ketamine to elicit a pro-resilience response against stress-induced maladaptive phenotypes was occluded when p11 was selectively deleted in serotonergic neurons. Altogether, we showed a previously unexplored role of the DRN circuit in regulating stress susceptibility and resilience-enhancing actions of ketamine.
- 26 November 2024
- Published by Springer Nature in Molecular Psychiatry
- Vol. 30 (6) , 2504-2516
Open AccessEnduring modulation of dorsal raphe nuclei regulates (R,S)-ketamine-mediated resilient stress-coping behavior
Ketamine may be a novel pharmacologic approach to enhance resilience and protect against stress-related disorders, but the molecular targets underlying this response remain to be fully characterized. The multifunctional protein p11 is crucial in the pathophysiology of depression and antidepressant responses. However, it is still unclear whether p11 plays a role in the pro-resilience effects induced by ketamine. Here, we demonstrated that prophylactic administration of ketamine buffers passive stress-induced maladaptive phenotypes induced by chronic stress exposure. Spatial neurotransmitter and metabolite analysis revealed that prophylactic ketamine was also effective in blunting stress-induced disturbances of tryptophan metabolism in dorsal raphe nuclei (DRN). Additionally, we demonstrated that ketamine prevented chronic restraint stress-induced p11 reduction in DRN, a highly p11-enriched region. Furthermore, we provide novel evidence indicating that p11 deficiency regulates susceptibility to stress-induced depression-related phenotypes, and these behavioral maladaptations are dependent, at least in part, on p11 function in serotonergic neurons. Spatial neurotransmitter and metabolite analysis also showed a reduction of tryptophan and dopamine metabolism in DRN of serotonergic p11-deficient mice. Viral-mediated downregulation of p11 within DRN induced a stress-susceptible phenotype. Finally, our results also unveiled that the ability of ketamine to elicit a pro-resilience response against stress-induced maladaptive phenotypes was occluded when p11 was selectively deleted in serotonergic neurons. Altogether, we showed a previously unexplored role of the DRN circuit in regulating stress susceptibility and resilience-enhancing actions of ketamine.
- Open Access
- 18 September 2024
- Published by Springer Nature in Nature Communications
- Vol. 15 (1) , 1-18
Claustrum and dorsal endopiriform cortex complex cell-identity is determined by Nurr1 and regulates hallucinogenic-like states in mice
The Claustrum/dorsal endopiriform cortex complex (CLA) is an enigmatic brain region with extensive glutamatergic projections to multiple cortical areas. The transcription factor Nurr1 is highly expressed in the CLA, but its role in this region is not understood. By using conditional gene-targeted mice, we show that Nurr1 is a crucial regulator of CLA neuron identity. Although CLA neurons remain intact in the absence of Nurr1, the distinctive gene expression pattern in the CLA is abolished. CLA has been hypothesized to control hallucinations, but little is known of how the CLA responds to hallucinogens. After the deletion of Nurr1 in the CLA, both hallucinogen receptor expression and signaling are lost. Furthermore, functional ultrasound and Neuropixel electrophysiological recordings revealed that the hallucinogenic-receptor agonists’ effects on functional connectivity between prefrontal and sensorimotor cortices are altered in Nurr1-ablated mice. Our findings suggest that Nurr1-targeted strategies provide additional avenues for functional studies of the CLA.
- 18 September 2024
- Published by Springer Nature in Nature Communications
- Vol. 15 (1) , 1-18
Open AccessClaustrum and dorsal endopiriform cortex complex cell-identity is determined by Nurr1 and regulates hallucinogenic-like states in mice
The Claustrum/dorsal endopiriform cortex complex (CLA) is an enigmatic brain region with extensive glutamatergic projections to multiple cortical areas. The transcription factor Nurr1 is highly expressed in the CLA, but its role in this region is not understood. By using conditional gene-targeted mice, we show that Nurr1 is a crucial regulator of CLA neuron identity. Although CLA neurons remain intact in the absence of Nurr1, the distinctive gene expression pattern in the CLA is abolished. CLA has been hypothesized to control hallucinations, but little is known of how the CLA responds to hallucinogens. After the deletion of Nurr1 in the CLA, both hallucinogen receptor expression and signaling are lost. Furthermore, functional ultrasound and Neuropixel electrophysiological recordings revealed that the hallucinogenic-receptor agonists’ effects on functional connectivity between prefrontal and sensorimotor cortices are altered in Nurr1-ablated mice. Our findings suggest that Nurr1-targeted strategies provide additional avenues for functional studies of the CLA.
- Open Access
Gut-Initiated Alpha Synuclein Fibrils Drive Parkinson's Disease Phenotypes: Temporal Mapping of non-Motor Symptoms and REM Sleep Behavior Disorder
Parkinson’s disease (PD) is characterized by progressive motor as well as less recognized non-motor symptoms that arise often years before motor manifestation, including sleep and gastrointestinal disturbances. Despite the heavy burden on the patient’s quality of life, these non-motor manifestations are poorly understood. To elucidate the temporal dynamics of the disease, we employed a mouse model involving injection of alpha-synuclein (αSyn) pre-formed fibrils (PFF) in the duodenum and antrum as a gut-brain model of Parkinsonism. Using anatomical mapping of αSyn-PFF propagation and behavioral and physiological characterizations, we unveil a correlation between post-injection time the temporal dynamics of αSyn propagation and non-motor/motor manifestations of the disease. We highlight the concurrent presence of αSyn aggregates in key brain regions, expressing acetylcholine or dopamine, involved in sleep duration, wakefulness, and particularly REM-associated atonia corresponding to REM behavioral disorder-like symptoms. This study presents a novel and in-depth exploration into the multifaceted nature of PD, unraveling the complex connections between α-synucleinopathies, gut-brain connectivity, and the emergence of non-motor phenotypes. One Sentence Summary Propagation of αSyn from the gut-to-the-brain induces RBD and several non-motor and motor phenotypes of Parkinson’s disease.
Open AccessGut-Initiated Alpha Synuclein Fibrils Drive Parkinson's Disease Phenotypes: Temporal Mapping of non-Motor Symptoms and REM Sleep Behavior Disorder
Parkinson’s disease (PD) is characterized by progressive motor as well as less recognized non-motor symptoms that arise often years before motor manifestation, including sleep and gastrointestinal disturbances. Despite the heavy burden on the patient’s quality of life, these non-motor manifestations are poorly understood. To elucidate the temporal dynamics of the disease, we employed a mouse model involving injection of alpha-synuclein (αSyn) pre-formed fibrils (PFF) in the duodenum and antrum as a gut-brain model of Parkinsonism. Using anatomical mapping of αSyn-PFF propagation and behavioral and physiological characterizations, we unveil a correlation between post-injection time the temporal dynamics of αSyn propagation and non-motor/motor manifestations of the disease. We highlight the concurrent presence of αSyn aggregates in key brain regions, expressing acetylcholine or dopamine, involved in sleep duration, wakefulness, and particularly REM-associated atonia corresponding to REM behavioral disorder-like symptoms. This study presents a novel and in-depth exploration into the multifaceted nature of PD, unraveling the complex connections between α-synucleinopathies, gut-brain connectivity, and the emergence of non-motor phenotypes. One Sentence Summary Propagation of αSyn from the gut-to-the-brain induces RBD and several non-motor and motor phenotypes of Parkinson’s disease.
- Open Access
- 12 March 2024
- Published by Springer Nature in npj Parkinson's Disease
- Vol. 10 (1) , 1
Author Correction: Generation of G51D and 3D mice reveals decreased α-synuclein tetramer-monomer ratios promote Parkinson’s disease phenotypes
- 12 March 2024
- Published by Springer Nature in npj Parkinson's Disease
- Vol. 10 (1) , 1
Open AccessAuthor Correction: Generation of G51D and 3D mice reveals decreased α-synuclein tetramer-monomer ratios promote Parkinson’s disease phenotypes
- Open Access
- 29 February 2024
- Published by Springer Nature in npj Parkinson's Disease
- Vol. 10 (1) , 1-12
Generation of G51D and 3D mice reveals decreased α-synuclein tetramer-monomer ratios promote Parkinson’s disease phenotypes
Mutations in the α-Synuclein (αS) gene promote αS monomer aggregation that causes neurodegeneration in familial Parkinson’s disease (fPD). However, most mouse models expressing single-mutant αS transgenes develop neuronal aggregates very slowly, and few have dopaminergic cell loss, both key characteristics of PD. To accelerate neurotoxic aggregation, we previously generated fPD αS E46K mutant mice with rationally designed triple mutations based on the α-helical repeat motif structure of αS (fPD E46K→3 K). The 3 K variant increased αS membrane association and decreased the physiological tetramer:monomer ratio, causing lipid- and vesicle-rich inclusions and robust tremor-predominant, L-DOPA responsive PD-like phenotypes. Here, we applied an analogous approach to the G51D fPD mutation and its rational amplification (G51D → 3D) to generate mutant mice. In contrast to 3 K mice, G51D and 3D mice accumulate monomers almost exclusively in the cytosol while also showing decreased αS tetramer:monomer ratios. Both 1D and 3D mutant mice gradually accumulate insoluble, higher-molecular weight αS oligomers. Round αS neuronal deposits at 12 mos immunolabel for ubiquitin and pSer129 αS, with limited proteinase K resistance. Both 1D and 3D mice undergo loss of striatal TH+ fibers and midbrain dopaminergic neurons by 12 mos and a bradykinesia responsive to L-DOPA. The 3D αS mice have decreased tetramer:monomer equilibria and recapitulate major features of PD. These fPD G51D and 3D mutant mice should be useful models to study neuronal αS-toxicity associated with bradykinetic motor phenotypes.
- 29 February 2024
- Published by Springer Nature in npj Parkinson's Disease
- Vol. 10 (1) , 1-12
Open AccessGeneration of G51D and 3D mice reveals decreased α-synuclein tetramer-monomer ratios promote Parkinson’s disease phenotypes
Mutations in the α-Synuclein (αS) gene promote αS monomer aggregation that causes neurodegeneration in familial Parkinson’s disease (fPD). However, most mouse models expressing single-mutant αS transgenes develop neuronal aggregates very slowly, and few have dopaminergic cell loss, both key characteristics of PD. To accelerate neurotoxic aggregation, we previously generated fPD αS E46K mutant mice with rationally designed triple mutations based on the α-helical repeat motif structure of αS (fPD E46K→3 K). The 3 K variant increased αS membrane association and decreased the physiological tetramer:monomer ratio, causing lipid- and vesicle-rich inclusions and robust tremor-predominant, L-DOPA responsive PD-like phenotypes. Here, we applied an analogous approach to the G51D fPD mutation and its rational amplification (G51D → 3D) to generate mutant mice. In contrast to 3 K mice, G51D and 3D mice accumulate monomers almost exclusively in the cytosol while also showing decreased αS tetramer:monomer ratios. Both 1D and 3D mutant mice gradually accumulate insoluble, higher-molecular weight αS oligomers. Round αS neuronal deposits at 12 mos immunolabel for ubiquitin and pSer129 αS, with limited proteinase K resistance. Both 1D and 3D mice undergo loss of striatal TH+ fibers and midbrain dopaminergic neurons by 12 mos and a bradykinesia responsive to L-DOPA. The 3D αS mice have decreased tetramer:monomer equilibria and recapitulate major features of PD. These fPD G51D and 3D mutant mice should be useful models to study neuronal αS-toxicity associated with bradykinetic motor phenotypes.